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Proposed collaboration:        
Genetic risk and progression to 
dementia in Parkinson’s disease. 
MDS - 2016 
New Zealand Brain Research Institute 
  and                            
Medical Genetics, UBC, Canada 
John Dalrymple-Alford, Tim Anderson, 
Matt Farrer, and colleagues. 
Objective: Time to PDD is a top priority. Establish a model, 
generated from a genetic risk score + other key factors, to estimate 
the probability of conversion to PDD over time: That is, an 
individualised probability, over time, expressed for each patient. 
Output from Model - cumulative probability of  PDD over time 
Baseline           0                               +4                          +8 yr 



































imputations for missing 




Example is for 72y PD 
with “MCI” at baseline. 
 
 
The aetiology of PDD, like PD, is multifactorial.         
Hence four key risk factors will be examined: 
 
• Age at assessment(s) (timepoint for interpreting motor and 
cognitive scores; not age at PD onset); 
• Motor phenotype (akinetic-rigid; tremor); 
• Poor cognition (eg. PD-MCI) is clearly a major risk factor; 
• Genetic risk → global model, but also comparison of risk factors. 
 
Novelty:  
• Addition of a genetic risk score, based primarily on relevant 
variability in the alpha-synuclein gene (SNCA); 
  
• Generation of a cognitive risk score, which may improve the 
predictive value of “MCI” and circumvent some of the problems of 
different test usage;  
 
• Improved knowledge of expected disease course / patient care; 
 
• Better intervention trials and analysis (targeted sample selection; 
genetically-based treatments / influences on response to therapy). 
Non-genetic data will include both information at baseline 
and ALL other available points longitudinally: 
 
• Conversions to PDD add more to model prediction, but it will 
benefit from inclusion of PDD at baseline and those who do 
not convert at last assessment. That is, it does not rely 
entirely on PDD conversion or avoid PDD status at baseline. 
PDD at baseline and 
Non-PDD at end is 
useful info, bc this 
adds info to the model 
(eg. partic gene score 
is associated with 
PDD or not for a 
given age). Two or 
more assessments 
contribute more. 
Genetic Risk: Variability in SNCA gene exists in sporadic Lewy 
Body diseases  (Guella….Farrer, 2016; Annals of Neurology). 
SNCA: confers the highest population-attributable risk of PD (GWAS). 
Method: Single nucleotide resolution analysis (43 SNPs).  




















Cognitive Risk Score: 
 
• Clearly, collaboration will make this project more viable, and – if 
agreed – we propose joining with other sites, espec PD-MCI sites 
initially (Amsterdam, Chicago, others; +PPMI). 
• All cognitive scores can be added at the time of model building, 
nested within site. 
 
• This means that site differences in particular Neuropsyc measures 
do not matter – the optimal measures predicting PDD will be 
identified, per site, for cognitive risk (better if some overlap). 
  
• This can also be generated independently to reveal within-site 
measures sensitive to conversion to PDD, and should be similar to 
the global model based on all 4 primary risk scores examined 
simultaneously (we are in the process of doing this for NZBRI 
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5 Cognitive DomainsNZBRI: Tests across 5 C gnitive Domains 
Probability 











Gaussian process with 
regularisation for 
selecting tests and 
generating risk scores. 
Maximise marginal 
likelihood to achieve 
good out-of-sample 
prediction performance. 
Checked by cross 
validation.
Can handle datasets 
with different sets of 
tests and generate 
comparable cognitive 
risk scores that can 
then be combined into a 
single analysis.
Best tests from NZBRI data for predicting 
dementia
NZBRI: Optimal tests for predicting PDD 
from our initial cohort 
Collaborations sought and possible extensions: 
 
• Coordinate through Gert and MDS PD-MCI consortium. 
• Initially, patients already processed by Matt Farrer and Ilaria 
Guella’s team. (Amsterdam; Chicago, NZBRI sites; n = 328). 
 
• *Funding - Apply to NZ-Health Research Council, Fox, +? 
Extensions:  
• (1) Validation: NZBRI has ~+100 extra PD; other sites? Level 1 
data from PPMI +?; validate the model’s predicted conversions in 
current / new patients over time. 
• (2) Neuroimaging: Association with composite / component PDD 
risk score (PDD-patterns: structural MRI; resting state networks; 
PET scans). 
• (3) Tx trials (eg. do cognitive/exercise efficacy / outcomes vary 
with composite / component risk score in ongoing / future trials?). 
• (4) Progression to MCI / genetic associations with MCI. 
….Thank you for your time… 
